Tranexamic acid for antenatal bleeding of unknown origin in the second and third trimesters: A prospective clinical trial

Ariana Khalis Jawad

doi:10.15218/zjms.2021.017

Authors

Ariana Khalis Jawad Department of Obstetrics and Gynecology, Kurdistan Board of Medical Specialties, Erbil, Iraq

DOI:

https://doi.org/10.15218/zjms.2021.017

Keywords:

Antifibrinolytic agent, Miscarriage, Neonatal death, Preterm labor, Tranexamic acid

Abstract

Background and objective: Vaginal bleeding is a common complication in pregnancy and is associated with poor perinatal outcomes. This study aimed to determine the efficacy of tranexamic acid in stopping vaginal bleeding during pregnancy and improving perinatal outcomes.

Methods: A prospective clinical trial was conducted on 137 pregnant women with vaginal bleeding of unknown causes in the second and third trimesters of pregnancy who were admitted to Maternity Teaching Hospital, Erbil city, Kurdistan region, Iraq from February 2016 to November 2019. Tranexamic acid was administered to one group and normal supportive care to another group in a sequential manner. The Mann–Whitney test was used to compare the mean rank of the times of admission. Factors that were significantly associated with stoppage of bleeding were entered into a binary logistic regression model.

Results: Bleeding was stopped in 90% of women who received tranexamic acid. There was a significant difference in low Apgar score, the rate of low birth weight, and the rate of unfavorable perinatal outcome in the supportive care group than that in the tranexamic acid group. Predictors for not stopping bleeding were supportive care management compared with tranexamic acid (odds ratio (OR) = 13.38; 95% confidence interval (CI) = 3.60–49.67), and 21–32 weeks gestation compared with ≥ 37 weeks (OR = 6.52; 95% CI = 1.66–25.63).

Conclusion: Tranexamic acid in second and third trimesters bleeding is effective for rapidly arresting bleeding with a favorable neonatal outcome.

Metrics

Metrics Loading ...

References

Sharami SH , Darkhaneh RF, Zahiri Z, Milani F, Asgharnia M, Shakiba M, et al. The relationship between vaginal bleeding in the first and second trimester of pregnancy and preterm labor. Iran J Reprod Med 2013; 11:385–9.

Magann FE, Cummings JE, Niederhauser A, Rodriguez-Thompson D, McCormack R, et al. Antepartum bleeding of unknown origin in the second half of pregnancy: a review. Obstet Gynecol Surv 2005; 60:741–5.

Sakornbut E, Leeman, L, Fontaine P. Late pregnancy bleeding. Am Fam Physician 2007; 75(8):1199–206.

Weiss JL, Malone FD, Vidaver J, Ball RH, Nyberg DA, Comstock CH, et al. Threatened abortion: a risk factor for poor pregnancy outcome, a population-based screening study. Am J Obstet Gynecol 2004; 190:745–50.

Calleja-Agius, J, Custo R, Brincat MP, Calleja N. Placental abruption and placenta praevia. Eur Clin Obstet Gynaecol 2006; 2:121–7.

Yang J, Savitz, DA. The effect of vaginal bleeding during pregnancy on preterm and small for gestational age births: US National Maternal and Infant Health Survey, 1988. Paediat Perinatal Epidemiol 2001; 15:34–9.

Pabinger I, Fries D, Schöchl H, Streif W, Toller W. Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis. Wien Klin Wochenschr 2017; 129(9):303–16.

Matteson KA, Rahn DD, Wheeler TL, Casiano E, Siddiqui NY, Harvie HS, et al. Nonsurgical management of heavy menstrual bleeding: a systematic review. Obstet Gynecol 2013; 121(3):632–43.

Movafegh A, Eslamian L, Dorabadi A. Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery. Int J Gynecol Obstet 2011; 115:224–6.

Andrea SL, Keith AM, Ken NM, Janet KG, Bryan RH, Måns E, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010; 116(4):865.

Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multicentre, randomized trial. Eur J Obstet Gynecol Reprod Biol 2004; 112(2):154–7.

World Health Organization. Updated WHO recommendation on tranexamic acid for the treatment of postpartum hemorrhage: highlights and key messages from the World Health Organization's 2017 global recommendation; 2017. Accessed May 25, 2020, at https://apps.who.int/iris/handle/10665/259379).

WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with postpartum hemorrhage (WOMAN): an international, randomized, double-blind, placebo-controlled trial. Lancet 2017; 389:2105–16.

Peitsidis P, Kadir RA. Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother 2011; 12(4):503–16.

Yang J, Hartmann KE, Savitz DA, Herring AH, Dole N, Andrew F. Vaginal bleeding during pregnancy and preterm birth. Am J Epidemiol 2004; 160(2):118–25.

Jin J. Babies with low birth weight. JAMA 2015; 313(4):432.

Lawn J, Gravett M, Nunes T, Rubens C, Stanton C. The GAPPS Review Group Global report on preterm birth and stillbirth (1 of 7): definitions, description of the burden and opportunities to improve data. BMC Pregnancy Childbirth 2010; 10(Suppl. 1):S1

The WHO application of ICD-10 to deaths during the perinatal period: ICD-PM. (Accessed July 9, 2021, at https://apps.who.int/iris/bitstream/handle/10665/249515/9789241549752-eng.pdf).

WHO: Preterm birth 2018. (Accessed 9, July 2021, at https://www.who.int/news-room/fact-sheets/detail/preterm-birth).

American Academy of Pediatrics—Committee on Fetus and Newborn (Replaces Committee Opinion Number 333, May 2006; Reaffirmed 2017). (Accessed May 10, 2020, at https://www.acog.org/Clinical- Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/The-Apgar-Score).

Levy JH, Koster A, Quinones QJ, Milling TJ, Key N. Antifibrinolytic Therapy and Perioperative Considerations. Anesthesiology 2018; 128(3): 657–70.

Podrasky AE, Javitt MC, Glanc PH, Dubinsky TH, Harisinghani MG, et al. ACR appropriateness criteria® second and third trimester bleeding. Ultrasound Q 2013; 29(4):293–301.

Bhandari S, Raja EA, Shetty A, Bhattacharya S. Maternal and perinatal consequences of antepartum hemorrhage of unknown origin. BJOG 2014; 121:44–52.

McCormack RA, Doherty DA, Magann RF, Hutchinson M, Newnham JP. Antepartum bleeding of unknown origin in the second half of pregnancy and pregnancy outcomes. BJGO 2008; 115(11):1451–7.

Dowswell T, Middleton P, Weeks A. Antenatal day care units versus hospital admission for women with pregnancy complications. Cochrane Database Syst 2009; 7(4):CD001803.